01 7Atozet
02 4Gadavist/Gadovist
03 2Gadovist product family
04 2Nilemdo/Nustendi
05 3Rosuzet
06 9Vytorin
07 10Zetia
08 1ZetiaTM
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 466
2019 Revenue in Millions : 524
Growth (%) : -11
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 453
2019 Revenue in Millions : 391
Growth (%) : 16
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 460
2020 Revenue in Millions : 466
Growth (%) : 9
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 183
2019 Revenue in Millions : 285
Growth (%) : -36
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 482
2019 Revenue in Millions : 590
Growth (%) : -18
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 458
2020 Revenue in Millions : 453
Growth (%) : 1
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 164
2020 Revenue in Millions : 182
Growth (%) : -10
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 22
2020 Revenue in Millions : 0
Growth (%) : 100
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 68
2020 Revenue in Millions : 130
Growth (%) : -48
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 378
2020 Revenue in Millions : 482
Growth (%) : -22
LOOKING FOR A SUPPLIER?